Sichuan Kelun Pharmaceutical Co., Ltd. (SHE:002422)
China flag China · Delayed Price · Currency is CNY
33.64
-0.39 (-1.15%)
May 8, 2026, 3:04 PM CST

SHE:002422 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
17,73417,86421,10720,71418,60116,936
Other Revenue
648.53648.53705.65739.64437.62341.23
18,38218,51321,81221,45419,03817,277
Revenue Growth (YoY)
-8.01%-15.13%1.67%12.69%10.19%4.94%
Cost of Revenue
9,8439,76710,61310,2919,0847,993
Gross Profit
8,5398,74611,20011,1639,9549,284
Selling, General & Admin
4,3054,2464,8015,5925,6575,877
Research & Development
2,3072,2052,1711,9441,7951,737
Other Operating Expenses
236.55154.79110.88184.61192.45150.4
Operating Expenses
6,8916,6417,1567,7567,6947,800
Operating Income
1,6482,1054,0443,4072,2601,484
Interest Expense
-99.43-102.84-151.62-361.54-475.22-518.34
Interest & Investment Income
294.25291.83416.62462.47278.81244.03
Currency Exchange Gain (Loss)
-45.57-45.5716.8933.36-41.86-2.31
Other Non Operating Income (Expenses)
95.642.32-170.39-18.95-143.9-21.84
EBT Excluding Unusual Items
1,8932,2514,1553,5221,8781,186
Impairment of Goodwill
-2.41-2.41----
Gain (Loss) on Sale of Investments
27.1827.6119.914.679.864.83
Gain (Loss) on Sale of Assets
5.885.320.812.635.4-7.94
Asset Writedown
-13.03-13.03-65.85-58.62-1.93-13.2
Legal Settlements
73.4173.41----
Other Unusual Items
87.5862.08175.0499.621778.38
Pretax Income
2,0722,4044,2853,5802,0681,178
Income Tax Expense
381.38526.62923.4933.79363.7309.5
Earnings From Continuing Operations
1,6901,8773,3622,6471,704868.12
Minority Interest in Earnings
-118.93-175.28-426.06-190.531.1234.44
Net Income
1,5711,7022,9362,4561,7051,103
Net Income to Common
1,5711,7022,9362,4561,7051,103
Net Income Growth
-36.99%-42.03%19.53%44.03%54.67%32.94%
Shares Outstanding (Basic)
1,5871,5911,5781,4531,3981,414
Shares Outstanding (Diluted)
1,5871,5911,5781,5451,4831,414
Shares Change (YoY)
-0.21%0.77%2.18%4.17%4.91%-1.15%
EPS (Basic)
0.991.071.861.691.220.78
EPS (Diluted)
0.991.071.861.591.150.78
EPS Growth
-36.86%-42.47%16.98%38.26%47.44%34.48%
Free Cash Flow
820.421,0202,8153,5682,2301,857
Free Cash Flow Per Share
0.520.641.782.311.501.31
Dividend Per Share
0.5940.5940.7630.8000.6160.426
Dividend Growth
-22.15%-22.15%-4.63%29.87%44.60%33.63%
Gross Margin
46.45%47.24%51.35%52.03%52.29%53.74%
Operating Margin
8.97%11.37%18.54%15.88%11.87%8.59%
Profit Margin
8.55%9.19%13.46%11.45%8.96%6.38%
Free Cash Flow Margin
4.46%5.51%12.90%16.63%11.71%10.75%
EBITDA
2,9623,3975,2494,5963,4162,690
EBITDA Margin
16.11%18.35%24.06%21.42%17.94%15.57%
D&A For EBITDA
1,3141,2921,2051,1891,1561,206
EBIT
1,6482,1054,0443,4072,2601,484
EBIT Margin
8.97%11.37%18.54%15.88%11.87%8.59%
Effective Tax Rate
18.41%21.91%21.55%26.08%17.59%26.28%
Revenue as Reported
18,38218,51321,81221,45419,03817,277
Advertising Expenses
-25.09145.44265.58129.59161.8
Source: S&P Global Market Intelligence. Standard template. Financial Sources.